Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women

Circulation

Volumn 109, Issue 5, 2004, Pages 672-693

  Mosca, Lori ^a   Appel, Lawrence J ^a   Benjamin, Emelia J ^a   Berra, Kathy ^a,c   Chandra Strobos, Nisha ^a   Fabunmi, Rosalind P ^a   Grady, Deborah ^e   Haan, Constance K ^k   Hayes, Sharonne N ^b   Judelson, Debra R ^f   Keenan, Nora L ^h   McBride, Patrick ^a   Oparil, Suzanne ^a   Ouyang, Pamela ^a   Oz, Mehmet C ^a   Mendelsohn, Michael E ^a   Pasternak, Richard C ^a   Pinn, Vivian W ^j   Robertson, Rose Marie ^a   Schenck Gustafsson, Karin ^a   Sila, Cathy A ^a   Smith Jr , Sidney C ^l   Sopko, George ⁱ   Taylor, Anne L ^g   Walsh, Brian W ^d   Wenger, Nanette K ^a   Williams, Christine L ^a   more..

^a AMERICAN HEART ASSOCIATION   (United States)

^b AMERICAN COLLEGE OF CARDIOLOGY   (United States)

^c Amer College of Nurse Practitioners   (United States)

^d American College of Obstetrics and Gynecology   (United States)

^e AMERICAN COLLEGE OF PHYSICIANS   (United States)

^f American Medical Women's Association   (United States)

^g Association of Black Cardiologists

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^j Office of Research on Women's Health   (United States)

^k The Society of Thoracic Surgeons   (United States)

^l WORLD HEART FEDERATION   (Switzerland)

more..

Author keywords

AHA Scientific Statements; Cardiovascular diseases; Prevention; Risk factors; Women

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; FOLIC ACID; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; STATINE; TRIACYLGLYCEROL; WARFARIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; DIET THERAPY; EVIDENCE BASED MEDICINE; FEMALE; HEART FAILURE; HEART INFARCTION; HEART REHABILITATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; SOCIAL PSYCHOLOGY; WEIGHT REDUCTION;

ADULT; AGED; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MIDDLE AGED; RECURRENCE; RISK FACTORS;

EID: 10744230501     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000114834.85476.81     Document Type: Review

References (26)

1. Mosca L, Grundy SM, Judelson D, et al. Guide to preventive cardiology for women. AHA/ACC scientific statement, consensus panel statement. Circulation. 1999;99:2480-2484.
2. American Heart Association. Heart disease and stroke statistics - 2003 update. Dallas, Tex: American Heart Association; 2002.
3. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-2753.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing group for the Women's Health Initiative investigators. JAMA. 2002;288:321-333. Summary for patients in: CMAJ. 2002;167:377-378, and J Fam Pract. 2002;51:821.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing group for the Women's Health Initiative investigators. JAMA. 2002;288:321-333. Summary for patients in: CMAJ. 2002;167:377-378, and J Fam Pract. 2002;51:821.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing group for the Women's Health Initiative investigators. JAMA. 2002;288:321-333. Summary for patients in: CMAJ. 2002;167:377-378, and J Fam Pract. 2002;51:821.
7. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. Women's Health Initiative investigators. N Engl J Med. 2003;349:523-534.
8. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. Women's Health Initiative investigators. JAMA. 2003;289:2673-2684.
9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) research group. JAMA. 1999;290:605-613.
10. Meinert CL, Gilpin AK, Unalp A, et al. Gender representation in trials. Control Clin Trials. 2000;21:462-475.
11. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
12. Smith S, Blair S, Bonow R, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577-1579.
13. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106: 388-391.
14. Gibbons R, Smith S, Antman E. American College of Cardiology/American Heart Association Clinical Practice Guidelines: Part I: where do they come from? Circulation. 2003;107:2979-2986.
15. Benjamin EJ, Smith SC, Cooper RS, et al. Task Force #1-magnitude of the prevention problem: opportunities and challenges. 33rd Bethesda Conference. J Am Coll Cardiol. 2002;40:588-603.
16. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Scientific statement of the American Heart Association Nutrition Committee. Circulation. 2002;106:2747-2757. Erratum in: Circulation. 2003;107:512.
17. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Scientific statement of the American Heart Association Nutrition Committee. Circulation. 2002;106:2747-2757. Erratum in: Circulation. 2003;107:512.
18. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572. Erratum in: JAMA. 2003;290:197.
19. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572. Erratum in: JAMA. 2003;290:197.
20. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care. 2003;26(suppl 1):S25-S27.
21. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type II diabetes with lifestyle intervention of metformin. N Engl J Med. 2002;346:393-403.
22. American College of Obstetricians and Gynecologists. Response to Women's Health Initative Study Results by the American College of Obstetricians and Gynecologists. June 3, 2003. Available at http://www.acog.com/member_access/misc/whiResponse.cfm.
23. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause. 2003;10:497-506.
24. D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. CHD Risk Prediction Group. JAMA. 2001;286:180-187.
25. Grundy SM, D'Agostino Sr RB, Mosca L. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation. 2001;104:491-496.
26. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499-503.